Multiple myeloma is a malignant disorder characterized by the proliferation of plasma cells. It accounts for 10% of hematological cancers and 1% of all cancers. The disease is uniformly fatal with a median survival of approximately three years with conventional chemotherapy (CC), although the outlook has improved with the integration of newer therapies including high-dose therapy followed by autologous stem cell transplantation (HDT-ASCT). Currently, multiple myeloma is the most common indication for ASCT in North America and Europe. ASCT remains the standard of care in eligible patients <65-70 years of age (although age is not a criteria in the US) performed either up-front or at relapse: it is mostly performed up-front after induction therapy. The attainment of complete response (CR) is held to be a surrogate for improved survival and is the aim of ASCT. patients. However, the median overall survival (OS) in patients achieving CR was 5.1 years compared with 3.3 years for other responders. 2 ASCT has helped improve CR and VGPR rates over and above CC and is usually performed after induction therapy as consolidation.
improvements in progression-free survival (PFS), and, OS and transplant-related mortality (TRM). [3] [4] [5] [6] [7] [8] CR rates, median PFS, median OS, and TRM have ranged from 17 to 44.5%, 25 to 42 months, 47.8 to 67 months, and 3 to 7%, respectively. ascribed to the fact that only responding patients were taken up for transplantation. Refractory patients who were enrolled for the study could also have derived benefit from ASCT.
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Two trials were designed to specifically examine the effect of up-front versus delayed ASCT (in case of relapse or refractory disease) on survival rates. There was no difference in OS, although the French trial reported higher CR rates and better PFS in favour of early transplantation. 6, 7 In another large US intergroup trial comparing CC with ASCT, no difference could be demonstrated, partly because the cross-over allowed for transplantation at relapse in patients on the CC arm, and also because the combination of total body irradiation (TBI) and melphalan dose of 140mg/m 2 rather than the standard 200mg/m 2 resulted in a disappointing CR rate of 17%.
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The trials incorporating melphalan and TBI had lower CR rates CR has been demonstrated to be the most important factor influencing long-term survival. In the IFM study, patients achieving a CR/VGPR had significantly higher five-year OS rates of 72% compared with 39%
among patients who had PR. 3 In a retrospective analysis of 721 newly diagnosed patients who underwent ASCT, it was found that patients achieving CR had a median survival of nine to 14 years compared with 5.9 years for patients who achieved PR.
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Attempts at Improving the Efficacy of Autologous Stem Cell Transplantation
Induction Therapy and the Effect of Autologous Stem Cell Transplantation
The most common treatment strategy involves use of induction chemotherapy followed by HDT-ASCT (in eligible patients).
Initial Regimens-Vincristine, Adriamycin, Dexamethasone/ Dexamethasone/Thalidomide, Dexamethasone
Initially, the most popular regimens used were single-agent pulsed dexamethasone or vincristine, adriamycin, and dexamethasone (VAD 14 Thus, ASCT seems to cover for the seeming inefficiencies of these induction regimens.
Newer Combinations-The Promise of Improved Results After Autologous Stem Cell Transplantation
Bortezomib and Dexamthasone
The combination of bortezomib and dexamethasone (VD) has been associated with RR ranging from 67 to 88% (VGPR or better rates ranging from 23 to 47%) and CR/nCR rates ranging from 13 to 21%. Post-ASCT, RR in the range of 90%, CR/nCR rates of up to 35%, and VGPR or better rates up to 62% have been described.
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Lenalidomide and Dexamethasone
Lenalidomide and dexamethasone (LD) use was associated with RR of 91% and CR rates of 18%. In patients who underwent ASCT, the two-year OS and PFS was 92 and 83%, respectively, compared with 90 and 59%, respectively, for those who did not undergo ASCT. However, the yield of stem cells diminished after prolonged use of this combination and therefore it has been suggested that an early stem cell harvest might be necessary in cases of patients planned for delayed ASCT. 21 
Bortezomib-based Combinations with Other Drugs
Bortezomib, doxorubicin, and dexamethasone (PAD) was evaluated as induction using bortezomib 1.3mg/m 2 (PAD1, n=21) or 1mg/m 2 (PAD2, n=20). CRs/VGPRs with PAD1/PAD2 were 62 and 42% post-induction and 81 and 53% post-transplantation, respectively. PFS (29 versus 24 months) and OS (two years 95 versus 73%) were statistically similar, but favoured PAD1 versus PAD2. 22 Therefore, standard-dose bortezomib was associated with better RRs compared with the lower dose in which the toxicity was lower. This result was also suggested in earlier reports.
With low-dose bortezomib, CR rates of 11% were seen that improved to 37% post-ASCT. 23 RR of 95% and CR rates of 24% were observed with standard-dose bortezomib, and post-ASCT CR rates improved to 57% (81% had VGPR or better responses.). 24 Liposomal, Doxorubicin-based Regimens
Bortezomib, liposomal doxorubicin, and dexamethasone have been used with RR of 93% (63% VGPR or better) and CR rates of 43%. Following ASCT, CR rates improved to 65% (75% of the responses were VGPR or better). 25 In regimens excluding dexamethasone (bortezomib, liposomal doxorubicin alone), RRs of 79% and CR rates of 28% have been observed. 26 The three-drug regimen of dexamethasone, vincristine, and liposomal doxorubicin (DVd) yielded RRs of 66%. 27 Four-drug regimens comprising 
Bortezomib and Thalidomide/Lenalidomide Combinations
The three-drug combination (VTD) of bortezomib, and TD has resulted in 87% RR and up to 36% CR/nCR rates. After ASCT CR/nCR rates improved to 57%. VGPR or better rates were seen in 77% of cases. In the Gruppo
Italiano Malattie EMatologiche dell'Adulto (GIMEMA) trial the high CR rates achieved after induction with VTD were not influenced by the presence of deletion 13 or t(4;14) thus suggesting their role in overcoming high-risk cytogenetics. 30 Use of VDT PACE (cisplatin, doxorubicin, dexamethasone, etoposide) resulted in OS of 89% and CR rates of 22%. After ASCT, CR/nCR rates improved to 75%. 31 The combination of lenalidomide, bortezomib, and dexamethasone yielded CR rates of 20% and RR of 87%. 32 Therefore,
ASCT improves on the RRs of the induction regimens including those incorporating newer agents.
The Role of Tandem Transplantation
Tandem transplantation has been used to improve the results of ASCT.
Sixty-nine percent CR rates were reported with tandem ASCT in a select group of patients. 33 Barlogie reported a 41% CR rate with such a strategy (total therapy). 34 has been suggested that the negative impact of having both cytogenetic abnormalities: deletion 13 and t(4;14) that were associated with very low VGPR rates with TD were offset by tandem transplantation. The VGPR rates were 12% in this subgroup of patients compared with 41-50% in patients with either of these abnormalities when given an induction regimen comprising TD. The three-year PFS and OS were nearly identical after tandem ASCT (70 versus 77% and 92 versus 88%, respectively). 37 
Incorporation of Newer Agents to Tandem Autologous Stem Cell Transplantation
The Total Therapy 2 (TT2) trial included thalidomide in the induction, consolidation, tandem ASCT, and maintenance strategy. After transplantation, the CR rate in the thalidomide arm was 62% versus no thalidomide 43%, and although the EFS improved (48 versus 38%) there was no difference in OS because of the more aggressive nature of the disease at relapse in those who were on thalidomide. 38, 39 The Total Therapy 3 trial has incorporated VDT-PACE into induction, consolidation, tandem ASCT, and maintenance strategy and reported 83% CR/nCR rates for patients 24 months into the programme. 40 With better CR/VGPR rates after a single ASCT following the incorporation of the newer induction regimens, the requirement of a tandem transplantation is expected to reduce.
Use of Drug Combinations-Bortezomib and Melphalan in the Conditioning Regimen
In a preliminary study, a combination of bortezomib and melphalan was used in the conditioning regimen in 35 poor-risk patients (including those who did not achieve VGPR after a first transplantation). Three months after ASCT, 63% VGPR including 31% CR was observed suggesting that the combination had the potential to surpass the responses observed with melphalan alone, but this would require confirmation from other studies, especially from those in which bortezomib was used as the induction regimen. Regimens such as melphalan, prednisone, and thalidomide (MPT), [42] [43] [44] melphalan, bortezomib, and prednisone (MPV), 45 and melphalan, prednisone, and lenalidomide (MPR) 46 have yielded impressive results with RR varying from 76 to 89% and CR rates ranging from 15.6 to 30%.
In fact, the MPT regimen was superior to the intermediate-dose
ASCT (melphalan 100mg/m 2 ). 44 However, the survival benefit has to be assessed against high-dose chemotherapy as against intermediate-dose
ASCT (melphalan 100mg/m 2 ) in order to claim whether these treatments are equivalent or superior to HDT-ASCT.
There is a debate as to whether patients in CR/nCR or even VGPR after induction therapy should be subjected to upfront ASCT or placed on maintenance therapy. In such situations, ASCT could then serve as a treatment option at relapse. The role of allogenic transplantation also keeps evolving but is tempered by the spectre of increased procedure 
